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Background: Chronic kidney disease–mineral and bone disorder (CKD–MBD) is a common complication in CKD
patients, particularly in those with end-stage renal disease that requires dialysis. Lanthanum carbonate (LC) is a
potent, non-aluminum, non-calcium phosphate binder. This systematic review evaluates the efficacy and safety of
LC in CKD-MBD treatment for maintenance-dialysis patients.
Methods: A systematic review and meta-analysis on randomized controlled trials (RCTs) and quasi-RCTs was
performed to assess the efficacy and safety of LC in maintenance hemodialysis or peritoneal dialysis patients.
Analysis was performed using the statistical software Review Manager 5.1.
Results: Sixteen RCTs involving 3789 patients were identified and retained for this review. No statistical difference
was found in all-cause mortality. The limited number of trials was insufficient to show the superiority of LC over
other treatments in lowering vascular calcification or cardiovascular events and in improving bone morphology,
bone metabolism, or bone turn-over parameters. LC decreased the serum phosphorus level and calcium ×
phosphate product (Ca × P) as compared to placebo. LC, calcium carbonate (CC), and sevelamer hydrochloride (SH)
were comparable in terms of controlling the serum phosphorus, Ca × P product, and intact parathyroid hormone
(iPTH) levels. However, LC resulted in a lower serum calcium level and a higher bone-specific alkaline phosphatase
level compared with CC. LC had higher total cholesterol and low-density lipoprotein (LDL) cholesterol levels
compared with SH. LC-treated patients appeared to have a higher rate of vomiting and lower risk of hypercalcemia,
diarrhea, intradialytic hypotension, cramps or myalgia, and abdominal pain. Meta-analysis showed no significant
difference in the incidence of other side effects. Accumulation of LC in blood and bone was below toxic levels.
Conclusions: LC has high efficacy in lowering serum phosphorus and iPTH levels without increasing the serum
calcium. Current evidence does not show a higher rate of adverse effects for LC compared with other treatments,
except for a higher incidence of vomiting. Moreover, LC accumulation in blood and bone was below toxic levels.
Well-designed studies should be conducted to evaluate the long-term effects of LC.
Keywords: Lanthanum carbonate, Chronic kidney disease mineral and bone disorder, Hemodialysis,
Peritoneal dialysis, Systematic review* Correspondence: lizihx@163.com
1Department of nephrology, West China Hospital of Sichuan University,
Chengdu, China
Full list of author information is available at the end of the article
© 2013 Zhang et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Zhang et al. BMC Nephrology 2013, 14:226 Page 2 of 14
http://www.biomedcentral.com/1471-2369/14/226Background
With the progression of renal failure, patients fre-
quently have disorders in bone and mineral metabol-
ism [1]. This group of disorders is collectively called
chronic kidney disease–mineral and bone disorder
(CKD–MBD) and includes pathogenically linked bio-
chemical abnormalities, bone diseases, and cardiovas-
cular (CV) and soft tissue calcification [1]. Gradual
decline in renal phosphorus clearance during CKD
progression leads to hyperphosphatemia [2], which is
a key factor in the development of MBD. Approxi-
mately 40% of dialysis patients reportedly suffer from
hyperphosphatemia [3]. Increasing evidence shows
that hyperphosphatemia promotes CV calcification [4]
and is an important predictor of mortality in end-
stage renal disease (ESRD) patients undergoing dialy-
sis [5-7]. Thus, lowering the serum phosphorus levels
is a promising therapeutic goal.
Serum phosphorus levels in ESRD patients can be
controlled by dietary restrictions, adequate dialysis
schedule, and oral phosphate binders. A number of
effective phosphate binders are currently available.
For several years, aluminum- and calcium-based salts
were widely used as phosphate binders because of their
high efficacy and low price. However, aluminum has well-
documented toxic effects that can lead to osteomalacia or
encephalopathy [8,9], whereas large doses of calcium-
based salts can contribute to CV calcification [10].
The use of aluminum- and calcium-free phosphate
binders may address these issues. Sevelamer hydro-
chloride (SH) is another useful phosphate binder for
ESRD patients [11,12]. However, its use is limited by
the associated metabolic acidosis and gastrointestinal
disorders as well as by the high dosage required to
achieve adequate phosphate control [11-14].
Lanthanum carbonate (LC) is another phosphate
binder that does not contain aluminum or calcium.
Lanthanum is a naturally occurring “rare-earth” elem-
ent that has a phosphate-binding capacity similar to
that of aluminum. However, it is poorly absorbed in
the human intestine and has an absolute oral bio-
availability of only 0.00089% [15,16]. Early studies in
dialysis patients with ESRD demonstrated the effects
of LC in lowering phosphorus levels during short-
term follow-up compared with a placebo and calcium
carbonate (CC) [17,18]. Recently published studies
observed the efficacy of LC in controlling the phos-
phorus level, reducing CV calcification [19], and in
altering bone morphology [20-22] during a longer
follow-up [21-24].
A previously published systematic review evaluated
the efficacy and safety of LC in CKD patients and
mainly focused on biochemical parameters [25]. We
conducted a systematic review of the efficacy and safetyof LC in ESRD patients undergoing dialysis, particularly
in terms of long-term outcomes such as mortality,
CV calcification, and bone disorder. The results were




Randomized controlled trials (RCTs) or quasi-RCTs (in
which allocation to treatment was obtained by alterna-
tion, alternate medical records, date of birth, or other
predictable methods) of LC in patients with hemodialysis
(HD) or peritoneal dialysis (PD) were searched in
MEDLINE, EMBASE, the Cochrane Renal Group
Specialised Register, and the Cochrane Central Regis-
ter of Controlled Trials (CENTRAL) using the follow-
ing criteria without any language restrictions:
“lanthanum carbonate OR Fosrenol AND (dialysis OR
hemodialysis OR peritoneal dialysis OR end stage
renal disease”. Animal or pediatric studies (with sub-
jects below 18 years of age) were excluded without
further review. Two authors independently screened
the titles and abstracts of the remaining studies and
discarded studies that were not applicable. However,
studies and reviews that possibly include relevant data
or information were initially retained. The latest date
for the search was March 31, 2013.
Studies
All RCTs and quasi-RCTs that investigated the safety
and effectiveness of LC in maintenance-HD or PD pa-
tients were considered eligible for inclusion.
Participants
ESRD patients who regularly receive HD or PD, aged ≥
18 years old, and did not use LC previously (at least > 1
week) were included in this study. Patients with any of
the following conditions were excluded:
1. Pregnancy or lactation.
2. Significant hypercalcemia [serum calcium > 11.0
mg/dL (2.75 mmol/L)] or hypocalcemia [serum
calcium < 7.9 124 mg/dL (1.98 mmol/L)].
3. Significant gastrointestinal disorders such as active
peptic ulcer, ulcerative colitis and Crohn’s disease,
intestinal obstruction, or fecal impaction.
4. Malignancy.
5. Any exposure to other investigational drugs within
30 days prior to the start of the study.Interventions
Intervention included the use of LC on ESRD patients
receiving HD or PD regardless of dosage, mode of
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sons were as follows:
1. LC + routine treatment versus placebo + routine
treatment.
2. LC + routine treatment versus calcium-based
binders (CBBs) + routine treatment.
3. LC + routine treatment versus SH + routine treatment.
4. LC + routine treatment versus other non-calcium
binders (NCBs) or previous phosphate binders +
routine treatment.
Routine treatment: HD or PD and supportive treatment.
Supportive treatment included methods that treat under-
lying kidney or medical diseases or improve other disorders
linked to kidney failure, such as anemia and hypertension.
Other medications for CKD-MBD treatment, such as
calcitriol and calcimimetics, could be used when needed,
but the use of such medications should be applied parallelly
both in the treatment group and the control group. Dietary
restriction was not mandatory. Routine treatments in the





Cardiovascular events were defined as fatal or nonfatal
myocardial infarction, fatal or nonfatal cerebrovascular event
(stroke), or the development of coronary artery disease.
Secondary outcomes
1. Vessel calcification (VC), including those of the
aorta, coronary artery, and cardiac valves, as
determined by spiral computed tomography.
2. Biochemical outcomes such as levels of serum
phosphorus, serum calcium, calcium × phosphate
product (Ca × P), intact parathyroid hormone
(iPTH), 1,25-(OH)D3, 25-(OH)2D3, total alkaline
phosphatase (TAP), bone-specific alkaline
phosphatase (BAP), and blood lipid.
3. Bone disorder (including bone morphology and bone
metabolism).
4. Lanthanum contents in bone, liver, and blood.
5. Inflammatory biomarker such as C-reactive protein
(CRP).
6. Side effects of medications.
Quality assessment
The quality of included studies was independently assessed
by two authors who were not blind to authorship orjournal of publication. The check list designed by the
Cochrane Renal Group was used. Disagreements were re-
solved by consulting with an independent third party. The
quality items assessed were the allocation concealment,
blinding, intention-to-treat analysis, and completeness of
follow-up. Blinding was assessed for investigators, partici-
pants, outcome assessors, and data analysts.
Data extraction and management
Data extraction was independently performed by two au-
thors using standard data-extraction forms. When more
than one publication of one study existed, reports were
grouped together, and the most recent or most complete
dataset was used. For studies that only displayed the re-
sults within diagrams from which data could not be re-
trieved, e-mails were sent to the authors to request for
accessible data.
Statistical analysis
Analyses were performed using Review Manager 5.1.
The results of dichotomous outcomes (all-cause mortal-
ity and cardiovascular events) were expressed as risk ra-
tios (RR) with 95% confidence intervals (CI). The mean
difference (MD) was obtained when continuous scales of
measurement were used to assess the treatment effects
(e.g., serum calcium, Ca × P, and iPTH), whereas the
standardized mean difference (SMD) was obtained when
different scales were used. Between-study heterogeneity
was assessed using the chi-square test. Random-effects
analysis was used when I2 > 50%, whereas fixed-effects
analysis was used when I2 < 50% [26].
Results
Search results
Literature search identified 867 articles, 846 of which
did not involve RCTs or quasi-RCTs and were thus ex-
cluded. Animal studies were also excluded. The full texts
of 21 articles were analyzed, and an additional 3 were
excluded because none of them met the inclusion cri-
teria [27-29]. After excluding 2 repeatedly published
studies [24,30], 16 articles [17-22,31-40] were identified
and retained for this review. The 16 studies involved
3789 patients, 2100 of which were in the LC groups and
1689 in the control groups (241 in the placebo group,
534 in the CBB group, 205 in the SH group, and 709 in
the NCB group) (Figure 1).
Characteristics of the included studies
The characteristics of the included studies are summa-
rized in Table 1. Fourteen studies were prospective RCTs,
whereas two were randomized crossover studies. All the
included studies were published in English. The two cross-
over studies [32,33] combined the data of phase 1 and
phase 2 (before and after exchange of treatment) together
Figure 1 Procedure used for the trial selection.
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phase. Three studies included HD and CAPD patients
[20,37,39]. Eleven studies included only HD patients. One
study included CAPD patients [39]. One study did not
mention what kind of the dialysis method was used in the
included patients [22]. Sample size ranged from 24 to
1359, and all but two studies had more than 500 partici-
pants [23,31].
The follow-up period ranged from 4 weeks to 3 years.
One study [21] observed 33 patients in the LC group
and 32 patients in the standard therapy group for 1 year
and 32 and 24 patients for 2 years, respectively. Another
study [22] followed up on 12 patients in the LC group
and 12 in the CC group after 1 and 3 years, respect-
ively. Only the data for the first year were complete
and were extracted for meta-analysis. In summary,
the follow-up periods of 9 studies were less than 24
weeks [17,32-38,40], those of 4 studies ranged from
24 weeks to 1 year [20,21,31,40], and those of 3 studies
were longer than 1 year [19,22,23].
In terms of intervention, 6 studies compared LC with
a placebo [17,34,36-38,40], 6 compared LC with CBBs
[19,20,22,31,34,39], 2 compared LC with SH [32,33], and
2 compared LC with previous phosphate binders [21,23].
Four studies [17,20,21,32] used calcitriol in the routine
treatment, whereas one study [17] used calcimimetics.
The baseline of the usage of above medication wereparallel between the LC group and the control group in all
of the studies.
Study quality
A summary of the quality measurements is shown in
Table 2. All 16 studies performed random allocation, but
only 2 [19,34] described the use of randomization. A con-
siderable part of the studies included in this review were
not blinded. Only 8 studies [17,32,34-38,40] reported
blinding of patients and physicians, and 1 [19] reported
blinding of outcome assessors. Intention-to-treat analysis
was performed in 10 of the 16 studies, and fulfillment of
follow-up was high in most of the studies except for two,
which had long follow-up durations.
Outcome
Effect on all-cause mortality
Only two studies [19,23] reported all-cause mortality of
patients using LC and other phosphate binders. No signifi-
cant difference was observed between the LC and the con-
trol in the risk of lowering all-cause mortality (2 studies,
1404 patients, RR: 0.85, 95% CI: 0.69 to 1.04).
Effect on cardiovascular events
Only one study [19] reported incidences of cardiovascu-
lar events. In the study, 3 in 22 LC-treated patients and
4 in 23 CC-treated patients experienced at least one
Table 1 Characteristics of trials of LC for CKD-MBD in dialysis patients
Study Intervention No. of patients Duration (Week) Dialysis methods
LC group Control group
Fouad Al-Baaj 2005 LC 375-2250 mg/d Placebo 36 4 HD
Melanie S. Joy 2003 LC 375 mg, 750 mg, 1500 mg, 2250 mg, 3000 mg/day Placebo 93 4 HD and CAPD
Finn WF 2006 LC<3000 mg/d (serum phosphate ≤5.9 mg/dl) pre-study phosphate binder (serum phosphate ≤5.9 mg/dl) 1359 104 HD
Patrick. C 2003 LC<3750 mg/d CC<9000 mg/d 98 52 HD
N. D TOUSSAINT 2011 LC (serum phosphate in the normal range) CC (serum phosphate in the normal range) 45 72 HD and CAPD
T.shigematsu 2008 LC+CC-liked placebo 750, 1500, 2250 mg/d (serum
phosphate at 3.5-5.5 mg/dl)
CC+LC-liked placebo 1500, 3000, 4500 mg/d(serum
phosphate 3.5-5.5 mg/dl)
258 8 HD
H H Mallache 2008 LC<3000mg/d (serum phosphate≤5.9mg/dl) Previous phosphate binder (serum phosphate ≤5.9 mg/dl) 65 52 HD
T.shigematsu 2007 LC 750 mg, 1500 mg, 2250 mg, 3000 mg/day Placebo 142 6 HD
Spasovski GB 2006 LC<3000 mg/d (serum phosphate <1.8 mmol/L) CC< 4000 mg/d (serum phosphate <1.8 mmol/L) 24 52 Not describe
A.J. Hutchison 2005 LC 250-3000 mg/d CC 1000-9000 mg/d 767 25 HD
S.-S. Chiang 2005 LC 375-3000 mg/d (can’t change during study) Placebo 61 4 HD
Finn WF 2004 LC 225 mg, 675 mg, 1350 mg, 2250 mg/day Placebo 144 6 HD
Yong Kyu Lee 2013 LC 1500 mg at start, regulate to control the serum
phosphate at 3.5-5.5 mg/dl
CC 3000 mg at start, regulate to control the serum
phosphate at 3.5-5.5 mg/dl
50 24 CAPD
Xu 2013 LC 1500 mg-3000 mg/day Placebo 230 4 HD and CAPD
Sprague S.M 2009 LC 3,000 mg/day SH 6,400 mg/day 333 4 HD

































Fouad Al-Baaj 2005 NS NS Yes Yes No No No 94
Melanie S. Joy 2003 NS NS Yes Yes No No Yes 87
Finn WF 2006 NS NS No No No No No 38
Patrick.C 2003 NS NS No No No No Yes 64
N. D TOUSSAINT 2011 Computer-generated
random numbers
Yes No No No Yes Yes 67
T.shigematsu 2008 NS NS Yes Yes No No Yes 99
H H Mallache 2008 NS NS No No No No No 47
T.shigematsu 2007 A single stream
scheme
Yes Yes Yes No No No 91
Spasovski GB 2006 NS NS NS NS NS NS No 83
A.J. Hutchison 2005 NS NS No No No No Yes 58
S.-S. Chiang 2005 NS NS Yes Yes No No Yes 69
Finn WF 2004 NS NS Yes Yes No No Yes 63
Yong Kyu Lee 2013 NS NS NS NS NS NS No 69
Xu 2013 NS NS Yes Yes NS NS Yes 99
Sprague, S.M 2009 NS NS Yes Yes NS NS Yes 90
Kasai, S 2012 NS NS NS NS NS NS Yes 95
NS: Not Stated.
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served between the LC and CBB groups in terms of the
risk of lowering cardiovascular events (1 study, 45 pa-
tients, RR: 0.78, 95% CI: 0.20 to 3.11).
Effect on vessel calcification
One study [19] reported an improvement in aortic vas-
cular calcification. In the study, patients were random-
ized to either LC (n=22) or CC (n=23). Patients in the
LC group showed significantly less aortic VC progres-
sion than those in the CC group (difference from base-
line −99.6 HU, 95% CI: –150.5 to −48.8, p < 0.001).
None of the trials reported calcification of the coronary
artery or cardiac valves.
Effects on biochemical outcomes
Fourteen studies [19-22,31-40] compared the serum
phosphorus level after treatment with LC with that of a
control. Six studies reported the results in diagrams only
and did not provide definite figures. The figures for two
studies were eventually acquired by writing the authors
[34,35]. The remaining four studies were not included
because the authors did not respond [20,21,23,32]. The
serum phosphorus levels were compared in 10 other stud-
ies, 5 of which compared LC with a placebo [34,36-38,40],
4 compared LC with CC [19,22,35,39], and 1 compared
LC with SH [33]. Meta-analysis showed that LC signifi-
cantly lowered the serum phosphorus level compared withthe placebo (5 studies, 562 patients, MD: –0.64, 95% CI: –
0.78 to −0.50), whereas no difference was observed be-
tween the LC and CC groups (4 studies, 377 patients,
MD: 0.09, 95% CI: 0.00 to 0.19) and between the LC and
SH groups (1 study, 84 patients, MD: –0.09, 95% CI: –
0.19 to 0.01) (Figure 2).
Seven studies [22,31,33-35,37,39] provided reports on
serum calcium levels. Analysis of their results showed
no difference between LC and the placebo (2 studies,
235 patients, MD: 0.05, 95% CI: –0.02 to 0.12) or be-
tween LC and SH (1 study, 84 patients, MD: 0.02, 95%
CI −0.03 to 0.07). CC-treated patients had higher cal-
cium levels than those treated with LC (4 studies, 1099
patients, MD: –0.12, 95% CI: –0.15 to −0.09) (Figure 3).
Seven studies [19,31,33,34,36,37,39] reported Calcium ×
Phosphate Product levels and showed that patients treated
with LC had lower Ca × P than those treated with a pla-
cebo (3 studies, 271 patients, MD: –1.43, 95% CI: –2.04
to −0.81). By contrast, no significant difference was ob-
served between LC and CC (3 studies, 862 patients, MD: –
0.14, 95% CI: –0.30 to 0.03) and between LC and SH
(1 study, 84 patients, MD: –0.16, 95% CI −0.39 to 0.07)
(Figure 4).
Four studies [22,33-35,37] reported the change in iPTH
levels and showed that LC-treated patients achieved lower
iPTH levels than those treated with placebos (2 studies,
235 patients, MD: –95.04, 95% CI: –151.10 to −38.98). By
contrast, no significant differences were observed between
Figure 2 Forest plot of serum phosphate level of patients treated with LC and control therapy. Studies were identified by name of the
first author and year of publication. Mean differences (MDs) were pooled using the random-effect model and shown on a scale of −1 to 1.
Figure 3 Forest plot of serum calcium in patients treated with LC and control therapy. Studies were identified by name of the first author
and year of publication. Mean differences (MDs) were pooled using the random-effect model and shown on a scale of −0.2 to 0.2.
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Figure 4 Forest plot of Ca × P product in patients treated with LC and control therapy. Studies were identified by name of the first author
and year of publication. Mean differences (MDs) were pooled using the random-effect model and shown on a scale of −2 to 2.
Zhang et al. BMC Nephrology 2013, 14:226 Page 8 of 14
http://www.biomedcentral.com/1471-2369/14/226LC and CC (2 studies, 282 patients, MD: 112.12, 95% CI: –
23.43 to 247.66) and between LC and SH (1 study, 84 pa-
tients, MD: 14.30, 95% CI: –27.83 to 56.43) (Figure 5).
Spasovski et al. [22] followed up the patients at 1 or 3
years after treatment and showed no difference betweenFigure 5 Forest plot of iPTH in patients treated with LC and control t
publication. Mean differences (MDs) were pooled using the random-effectthe 1,25-(OH)D3 levels of the LC and CC groups (1 study,
24 patients, MD: –0.80, 95% CI: –27.16 to 25.56). In a
similar manner, no difference was observed between the
25-(OH)2D3 levels (1 study, 24 patients, MD: 11.00, 95%
CI: –6.21, to 28.21) and TAP (1 study, 24 patients, MD:herapy. Studies were identified by name of the first author and year of
model and shown on a scale of −500 to 500.
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One study compared LC with SH and showed no differ-
ence in TAP (1 study, 84 patients, MD: 7.00, 95% CI: –
55.03 to 69.03). Three studies [22,23,31] reported the BAP
levels; patients in the LC group had higher BAP than
those who continued to use the previous phosphate binder
(1 study, 1359 patients, MD: 4.90, 95%: CI 2.73 to 7.07).
By contrast, no difference was found between the BAP
levels of LC and CC (1 study, 24 patients, MD: 2.50, 95%
CI: –10.44 to 15.44) and between LC and SH (1 study, 84
patients, MD: 1.30, 95% CI: –6.55 to 9.15).
The results also showed that when compared with the
SH group, the LC group had higher levels of total chol-
esterol (1 study, 84 patients, MD: 25.00, 95% CI: 12.17
to 37.83) and LDL cholesterol (1 study, 84 patients, MD:
20.00, 95% CI: 10.16 to 29.84) [33]. Other studies did
not investigate the difference between the lipid levels of
the LC and control groups (placebo, CC, or previous
phosphate binders).
Bone disorder
Three studies [20-22] involved patients who received at
least one bone biopsy. However, these studies used dif-
ferent parameters that a meta-analysis was not possible.
D’Haese et al. [20] performed bone biopsy in 33 patients
in the LC group and 30 patients in the CC group at the
baseline and one year after treatment, respectively. The
subtypes of bone diseases were similarly distributed in
both groups at the baseline. In the LC group, the num-
ber of patients with renal osteodystrophy (ROD) de-
creased from 12 (36%) at the baseline to 6 in the 1-year
follow-up (18%), whereas that in the calcium group in-
creased from 13 (43%) to 16 (53%). One patient in the
LC group and 6 in the CC group evolved toward ady-
namic bone.
Malluche et al. [21] performed bone biopsy in 32 pa-
tients in the LC group and 33 patients in the CC group at
the baseline and 1 and 2 years after treatment. Their re-
sults showed that under similar phosphorus control, the
LC group showed improvements in the bone turnover
and bone volume; the improvements were particularly sig-
nificant in the 1-year and 2-year groups, respectively. No
significant change in the bone turnover or bone volume
was observed in the standard phosphate-binder therapy
group. Spasovski et al. [22] followed up on patients 1 or 3
years after treatment and did not observe any differences
in the osteoblast numbers and mineral apposition rates
between the LC and CC groups.
Lanthanum contents in bone, liver, and blood
Seven studies [20,22,23,31,34,37,38] measured the plasma
or serum lanthanum level. Most of the results showed
slightly increased lanthanum levels in the blood of the LC
groups but did not indicate any statistical difference,except in one study [22], which reported significantly
higher plasma lanthanum levels in the LC group com-
pared with that in the CC group. No study reported lan-
thanum contents exceeding the limit of quantification, a
condition that would be harmful to the body. Three stud-
ies [20-22] detected the lanthanum content in the bone
and showed no significant difference in the bone lan-
thanum contents between LC and control group. Meta-
analysis was not performed because the unit for lan-
thanum content varied among the studies. No study
reported the lanthanum content in the liver or other
organs.
Inflammatory biomarker
None of trials reported any inflammatory biomarker
such as CRP.
Side effects of medications
Only 4 studies [19-21,39] did not evaluate the side ef-
fects of medications. Results showed that LC had a lower
risk of diarrhea when compared with placebo (4 studies,
395 patients, RR 0.31, 95% CI 0.15 to 0.65). When com-
pared with CBBs, there was a higher rate of vomiting
(2 studies, 1058 patients, RR 1.51, 95% CI 1.08 to 2.12) and
a lower rate of hypercalcaemia (5 studies, 1220 patients,
RR 0.12, 95% CI 0.04 to 0.38) in patient treated with LC.
Our meta-analysis also showed that when compared with
previous phosphate binders, there was a lower rates of
intradialytic hypotension (1 study, 1359 patients, RR: 0.66,
95% CI: 0.53 to 0.82), cramps or myalgia (1 study, 1359 pa-
tients, RR: 0.76, 95% CI: 0.63 to 0.92), and abdominal pain
(1 study, 1359 patients, RR: 0.73, 95% CI: 0.59 to 0.91) in
LC-treated patient. No significant differences were found
in the incidences of nausea, constipation, bronchitis,
dyspepsia, rhinitis, pruritus, and dialysis complications
(Table 3).
Discussion
A comprehensive search for RCTs was performed to
evaluate the efficacy and safety profile of lanthanum in
maintenance-dialysis patients. A total of 16 trials involving
3789 patients met our criteria and were enrolled in our
meta-analysis. Our results show no lanthanum-induced
decrease in all-cause mortality or cardiovascular events.
Only one RCT [19] reported on vascular calcification and
showed that lanthanum delayed the progression of aortic
calcification compared with CC. Lanthanum efficiently
lowered the serum phosphorus, Ca × P, and iPTH levels
compared with placebos. Moreover, lanthanum showed
equal efficiency in lowering serum phosphorus, Ca × P,
and iPTH levels as calcium bicarbonate but with a lower
serum calcium level. No statistical differences in 1,25-
(OH)D3, 25-(OH)2D3 and TAP were observed between
lanthanum and CC. However, lanthanum caused a
Table 3 Side-effects of medications
Fixed-effects model Random-effects model Heterogeneity
RR (95% CI) P value RR (95% CI) P value P value I2 (%)
Vomiting 1.06 [0.91, 1.23] 0.45 1.22 [0.81, 1.84] 0.33 0.04 54%
LC vs Placebo 2.35 [0.95, 5.80] 0.06 1.87 [0.55, 6.37] 0.32 0.22 32%
LC vs CBBs 1.51 [1.08, 2.12] 0.02 1.51 [1.08, 2.11] 0.02 0.37 0%
LC vs previous phosphate binders 0.90 [0.76, 1.06] 0.20 0.90 [0.76, 1.06] 0.20 - -
Diarrhea 0.79 [0.68, 0.93] 0.003 0.69 [0.40, 1.18] 0.17 0.001 70%
LC vs Placebo 0.31 [0.15, 0.65] 0.002 0.29 [0.14, 0.62] 0.001 0.53 0%
LC vs CBBs 1.29 [0.84, 1.98] 0.24 1.29 [0.84, 1.98] 0.24 - -
LC vs previous phosphate binders 0.75 [0.63, 0.90] 0.001 0.75 [0.63, 0.90] 0.001 - -
Nausea 1.03 [0.91, 1.17] 0.61 1.25 [0.85, 1.84] 0.26 0.06 52%
LC vs Placebo 2.06 [0.82, 5.16] 0.12 1.60 [0.49, 5.16] 0.43 0.26 27%
LC vs CBBs 1.42 [1.01, 2.01] 0.05 1.80 [0.70, 4.64] 0.22 0.09 66%
LC vs previous phosphate binders 0.93 [0.81, 1.07] 0.32 0.93 [0.81, 1.07] 0.32 - -
Constipation 0.72 [0.46, 1.12] 0.14 0.70 [0.36, 1.35] 0.29 0.23 31%
Hypercalcaemia 0.10 [0.06, 0.16] <0.00001 0.12 [0.04, 0.38] 0.0002 0.009 71%
LC vs CBBs
Intradialytichypotension 0.70 [0.58, 0.85] 0.0004 0.72 [0.54, 0.96] 0.03 0.28 21%
LC vs Placebo 3.10 [0.34, 28.17] 0.31 3.10 [0.34, 28.17] 0.31 - -
LC vs CBBs 0.83 [0.51, 1.36] 0.47 0.83 [0.51, 1.36] 0.47 - -
LC vs previous phosphate binders 0.66 [0.53, 0.82] 0.0002 0.66 [0.53, 0.82] 0.0002 - -
Cramps or Myalgia 0.81 [0.68, 0.97] 0.02 0.83 [0.65, 1.07] 0.15 0.32 13%
LC vs Placebo 1.29 [0.38, 4.35] 0.68 1.29 [0.38, 4.35] 0.68 - -
LC vs CBBs 1.12 [0.64, 1.95] 0.69 1.12 [0.64, 1.95] 0.69 - -
LC vs NCBs 0.76 [0.63, 0.92] 0.005 0.76 [0.63, 0.92] 0.005 - -
Abdominal pain 0.75 [0.61, 0.92] 0.006 0.74 [0.60, 0.91] 0.004 0.64 0%
LC vs Placebo 2.14 [0.40, 11.44] 0.37 1.93 [0.35, 10.55] 0.45 0.56 0%
LC vs CBBs 0.60 [0.18, 2.00] 0.40 0.60 [0.18, 2.00] 0.40 - -
LC vs previous phosphate binders 0.73 [0.59, 0.91] 0.004 0.73 [0.59, 0.91] 0.004 - -
Bronchitis 0.82 [0.66, 1.03] 0.08 0.82 [0.66, 1.03] 0.08 0.97 0%
Dyspepsia 0.24 [0.09, 0.61] 0.003 0.21 [0.04, 1.17] 0.007 0.13 52%
LC vs Placebo
Rhinitis 1.20 [0.69, 2.08] 0.52 1.20 [0.69, 2.08] 0.52 0.64 0%
Pruritus 4.04 [0.56, 29.27] 0.17 3.84 [0.48, 30.48] 0.20 0.55 0%
LC vs Placebo
Dialysis complication 0.68 [0.39, 1.17] 0.16 0.67 [0.38, 1.16] 0.15 0.39 0%
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http://www.biomedcentral.com/1471-2369/14/226statistically significant increase in the BAP level compared
to previous phosphate binder. No differences were ob-
served between SH and LC in controlling serum phos-
phorus, serum calcium, TAP, and BAP levels. However,
SH reduced the total cholesterol and the LDL cholesterol
levels. The efficacy of lanthanum on bone disorder was
reported in only a few studies, and different parameters
were used. Thus, our meta-analysis cannot draw reliable
conclusions.The two trials that observed all-cause mortality
reported no difference in the risks of all-cause mortality
between lanthanum and calcium bicarbonate [19] or
standard therapy (without lanthanum) [23]. Wilson et al.
[24] performed a trial involving 1354 patients and
conducted follow-up examinations for 40 months. The
study contributed 98.9% of the weight in our all-cause
mortality analysis because of its large sample size. The
study found no significant difference between the overall
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and standard therapy [23.3% (157/674)]. Subgroup ana-
lysis showed that the mortality for patients aged > 65
years was significantly lower in the LC treatment than in
the standard therapy. This trend is highly similar to that
of the Dialysis Clinical Outcomes Revisited (DCOR)
study [41], which is the largest randomized comparator-
controlled trial that assessed the mortality risks of non-
calcium-based binders (sevelamer) and CC.
Vascular calcification is a common and severe problem
associated with mortality in adult ESRD patients [42].
LC was demonstrated to attenuate the progression of
vascular calcification in several animal models [43,44].
In the present analysis, only one trial [19] observed this
outcome and reported that compared with CC, lanthanum
carbonate was associated with the reduced progression of
aortic calcification in 30 HD patients for over 18 months.
Additional clinical studies involving large sample sizes and
long-term follow-up must be conducted to determine
whether lanthanum confers the advantage of inhibiting vas-
cular calcification to dialysis patients. A prospective, large-
scale observational study [Study of Hyperphosphatemia in
CKD5D Patients Undergoing Hemodialysis (STOP-HD
trial): UMIN-ID 000002002] is currently underway to con-
firm the inhibitory effect of LC on vascular calcification.
The results of this study are being anticipated.
A small number of trials performed bone biopsy; how-
ever, the efficiency on bone disorder was difficult to
evaluate. Two trials [20,21] found improvements in renal
osteodystrophy in lanthanum-treated patients compared
with those treated with CC or with their previous phos-
phate binders (without lanthanum). However, another
trial [22] showed no difference between the two binders.
D’Haese et al. [20] found that the number of patients
with renal osteodystrophy decreased in the lanthanum
group, whereas that in the CC group increased. Malluche
et al. [21] found an improvement in bone turnover during
the first year as well as a significant improvement in bone
volume during the second year. By contrast, Spasovski
et al. [22] found no significant differences in the osteoblast
number, bone formation rate, osteoid volume, or mineral
apposition rate in the lanthanum and CC groups after a
one-year treatment. None of these trials found association
with aluminium-like bone toxicity after treatment of lan-
thanum. A standard and uniform evaluation system for
bone disorder in CKD-MBD must be established to im-
prove the assessment of the effects of LC on ROD.
Sevelamer is another calcium- and aluminum-free
phosphate binder. A small number of studies directly
compared this binder with LC. Only two cross-over stud-
ies were identified, and our meta-analysis showed that the
two treatments were similarly effective in controlling
serum calcium and phosphorus levels. However, compared
with LC, SH can improve the lipid profile by reducing thetotal cholesterol and LDL levels. SH differs from other
phosphate binders because of its unique ability to reduce
the levels of serum cholesterol and proinflammatory fac-
tors. However, it also increases the risks of hyperchloremic
metabolic acidosis and hyperkalemia. Sevelamer binds to
bile acids probably because of its physiochemical similar-
ities to common bile sequestrants. This characteristic al-
lows sevelamer to interfere with fat absorption and reduce
LDL cholesterol levels [45]. In addition, sevelamer can
physicochemically bind to the negatively charged lipid A
portion of endotoxin (ET). In vitro experiments showed
that SH can bind to ET in a dose-dependent manner [46].
Moreover, an in vivo experiment demonstrated that
sevelamer can reduce ET which was triggered by renal
failure [47]. Previous trials [48-50] showed that compared
with calcium-containing phosphate binders, sevelamer re-
duces the levels ET and proinflammatory markers such as
CRP, interlekin-6, endothelin-1, and plasminogen activator
inhibitor-1 in dialysis patients. In patients with early dia-
betic CKD, sevelamer carbonate significantly reduces
HbA1c, fibroblast growth factor 23, lipids, tumor necrosis
factor-α, and oxidative stress compared with CC [51].
However, the studies included in our systematic review
did not compare the anti-inflammatory effects of LC and
SH. Compelling preliminary data demonstrate that the
ET-binding effect and anti-inflammatory activity of SH are
associated with the improvement of mortality in ESRD
compared with those of calcium-containing phosphate
binders [52]. Long-term clinical trials must be conducted
to confirm the relationship between the amelioration of
lipid metabolism and the improvement of patient survival.
In particular, we recommend that additional studies be
performed to determine if the lipid-lowering effect or
anti-inflammatory activity of SH can improve the clinical
outcome for CKD–MBD patients compared with LC.
The included studies did not compare the serum bi-
carbonate and potassium levels of the different groups.
Moreover, the risks of acidosis and hyperkalemia of SH
were unknown. Sevelamer carbonate is an improved,
buffered form of SH that has equivalent efficacy in con-
trolling phosphate levels but has a lower incidence of
the above adverse effects [53]. Future RCTs that com-
pare LC and sevelamer carbonate is also recommended.
The safety of LC has received considerable concern.
All of the studies included in this paper reported that
the accumulation of LC in both blood and bone was
below toxic levels. After six years of LC treatment, the
incidences of fractures and bone-related musculoskeletal
adverse events were also significantly low [54]. In addition
to that in bone, lanthanum accumulation in the liver
should also be a point of concern because LC is excreted
through bile. Although increased liver lanthanum depos-
ition after oral lanthanum loading in uremic rats in com-
parison with normal renal function rats was observed
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thanum was present in the lysosomes of hepatocytes and
was mostly concentrated in the biliary poles of the hepato-
cytes and within the bile canaliculi [57]. No lanthanum
was detected in the hepatocyte mitochondria, nucleus, or
cytoplasm. The six-year, long-term clinical observation
also showed that liver enzymes did not increase, and that
the few cases of liver- or biliary-related adverse events,
none of which were considered to be related to lan-
thanum, were mainly observed in the first two years of
treatment [54]. However, one case study reported that
lathanum induced abnormal liver function in one male
patient with PD and in one female patient with HD [58].
Our systematic review cannot provide sufficient evidence
to show the safety of lanthanum in liver function. There-
fore, future studies should also investigate the concentra-
tion and possible toxicity of lanthanum in the liver.
The most commonly reported side effects were gastro-
intestinal adverse events. Our meta-analysis showed no
differences in nausea, constipation, and dyspepsia. The
prevalence of vomiting was significantly higher in LC
compared with that in CC. LC had lower risks of diar-
rhea and intradialytic hypotension compared with place-
bos and previous phosphate binders, respectively. Other
side effects included dialysis complications, bronchitis,
rhinitis, and pruritus while no significant differences
were found between the treatments. One study showed
that LC-treated patients had lower risks of intradialytic
hypotension, diarrhea, cramps or myalgia, and abdom-
inal pain compared with those treated with their previ-
ous phosphate binders.
Note that the effects of the dialysis type, dialysis dose,
session duration, membrane type, and dialytic modality
on phosphate removal were not assessed in the meta-
analysis. Only four trials included patients with peritoneal
dialysis. Therefore additional RCTs should be conducted to
investigate the effects of lanthanum in peritoneal-dialysis
patients.
To our knowledge, this study is the first to conduct a
comprehensive systematic review of RCTs that assessed
the advantages and disadvantages of using lanthanum
treatment for CKD-MBD in dialysis patients. A previous
[25] systematic review evaluated the effects of all phos-
phate binders on CKD-MBD in patients with CKD and
also confirmed the efficacy of lanthanum in reducing the
phosphorus levels (similar to that of CC) and lowering
the incidence of hypercalcemia. However, the study did
not evaluate the effects of lanthanum on mortality, vas-
cular calcification, and bone disorder. Moreover, it did
not provide the detailed side effects of lanthanum on
bone, plasma, and liver contents nor include peritoneal-
dialysis patients. Other published meta-analyses focused
only on SH [59] or included both observational studies
and RCTs [60].Our systematic review has a number of limitations. Ex-
cept for two trials with large sample sizes of 1359 [23]
and 767 [31], most of the trials enrolled a limited num-
ber of patients. The duration of half of these trials
ranged from 4 weeks to 8 weeks. The key findings are
limited by the lack of long-term studies on mortality,
cardiovascular events, cardiovascular calcification, and
bone disorder. Most of the included trials only observed
the biochemical parameters without considering patient-
focused outcomes. Moreover, this review did not evalu-
ate the health economic effectiveness of LC. Although
LC can reduce the serum phosphorus level and has a
lower risk of vascular calcification and hypercalcemia, it
is a rare metal that is more valuable than calcium. A
number of studies focused on the cost-effectiveness ratio
of phosphate binders [61,62]. One study [61] showed
that LC is cost-effective as a second-line treatment for
patients who are not adequately maintained on CC
(serum phosphorus above 5.6 mg/dL). Therefore, a sys-
tematic review that evaluates the health economic effect-
iveness of LC must be conducted to serve as a guideline
for clinicians in providing individualized therapies for
different patients, particularly for those in developing
countries.
Conclusions
The results of this meta-analysis show that lanthanum
efficiently lowers the serum phosphorous and iPTH
levels without elevating the serum calcium level. Apart
from a higher incidence of vomiting, LC did not demon-
strate higher incidence rates of other adverse effects
compared with other treatments. Moreover, the accumu-
lation of LC in blood and bone was below toxic levels.
Current evidence is insufficient to demonstrate that lan-
thanum is superior to other phosphate binders in terms of
lowering mortality, cardiovascular events, and vascular
calcification as well as of improving bone disorder. Future
studies with larger sample sizes and longer durations must
be conducted to assess the effects of lanthanum on not
only biochemical outcomes, but also on mortality, cardio-
vascular events, vascular calcification, and bone disorder.
In addition, comparison with sevelamer carbonate, safety
in bone and liver, health economic effectiveness, dialysis
method and prescription should also be concerned in the
future studies with LC.
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